12:00 AM
 | 
Sep 06, 2010
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Afferent, Roche preclinical data

In a rat model of bone cancer pain, 100 mg/kg twice-daily oral AF-353 significantly prevented and reversed bone cancer pain behavior vs. vehicle-treated controls....

Read the full 97 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >